Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000322980 | SCV000330211 | pathogenic | not provided | 2016-02-10 | criteria provided, single submitter | clinical testing | A novel pathogenic variant has been identified in the CASR gene. The c.2364 C>G nucleotide change leading to the F788L amino acid substitution has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. This substitution occurs at a position that is conserved across species. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. However, a separate nucleotide change in the same codon, c.2362 T>C,leads to the same F788L missense change, was published in association with hypocalcemia (Hendy et al., 2003) and has been classified as pathogenic. Additionally, another pathogenic missense variant in the same codon, F788C, has been published in association with CASR-related disorders (Watanabe et al., 1998; Kinoshita et al., 2014). Therefore, the c.2364 C>G (F788L) is pathogenic. |